Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 20/20 | 0.64 |
| ▸ | KDR | P35968 | 20/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 16/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 15/20 | 0.64 |
| ▸ | FLT3 | P36888 | 9/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788136 | 0.88 | FGFR3 (0.79) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL16125106 | 0.87 | FGFR4 (0.60) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22060565 | 0.87 | FGFR3 (0.66) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL18685235 | 0.87 | FGFR3 (0.83) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL18685439 | 0.87 | FGFR3 (0.62) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL18720510 | 0.86 | FGFR3 (0.65) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22060927 | 0.85 | FGFR3 (0.76) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL17132897 | 0.83 | FGFR3 (0.83) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL14788085 | 0.83 | FGFR3 (0.74) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL18685246 | 0.82 | FGFR3 (0.78) | FGFR3KDRFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155555-B2 | Compounds | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-26 | — | — | US | disclosed |
| US-20200255430-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-13 | — | — | US | disclosed |
| EP-3353177-B1 | TRICYCLIC HETEROCYCLES FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-03 | — | — | EP | disclosed |
| US-10421747-B2 | Quinoxaline derivatives useful as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20180186775-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180186775-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2018-07-05 | — | — | US | disclosed |
| US-9902714-B2 | Quinoxaline derivatives useful as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902714-B2 | Quinoxaline derivatives useful as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20170101396-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2017-04-13 | — | — | US | disclosed |
| US-20170101396-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2017-04-13 | — | — | US | disclosed |
| WO-2017050864-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | WO | disclosed |
| WO-2015144803-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101396-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885KDR 101/4885FGFR1 1/4885 |
| US-20180186775-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | FGFR1, FGFR3, FGFR4 | FGFR3 2/4885KDR 100/4885FGFR1 1/4885 |
| US-11155555-B2 | Compounds | NQO2, NQO1, SDHA | FGFR3 3987/4885KDR 3902/4885FGFR1 4133/4885 |
| US-10421747-B2 | Quinoxaline derivatives useful as FGFR kinase modulators | FGFR1, FGFR3, FGFR4 | FGFR3 2/4885KDR 100/4885FGFR1 1/4885 |
| US-20200255430-A1 | NEW COMPOUNDS | NQO2, NQO1, SDHA | FGFR3 4265/4885KDR 3823/4885FGFR1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.